Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bailing capsule plus methimazole versus methimazole alone for Graves' disease
ChiCTR2300072290Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bailing jiaonang and methimazole in Graves' disease (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Difference of TRAb titer from baseline. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
bailing jiaonangmethimazole
03
Conditions
Graves' disease
Beyond the preview
Go deeper on ChiCTR2300072290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072290.